Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Joshua M. Ruch"'
Autor:
David Bing Zhen, Jason E. Savage, Joshua M. Ruch, Kevin Camphausen, Diane M. Simeone, Kent A. Griffith, Mark M. Zalupski, Vaibhav Sahai, Edward J. Kim
Publikováno v:
Investigational new drugs, vol 34, iss 6
Invest New Drugs
Invest New Drugs
Background Cabozantinib and gemcitabine improve tumor control in pancreatic ductal adenocarcinoma (PDAC) in preclinical models through c-Met inhibition. We sought to determine the maximum tolerated dose (MTD) of this combination in patients with adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fef9611dd4d43344519c5cae73c7609f
https://escholarship.org/uc/item/8089j2w4
https://escholarship.org/uc/item/8089j2w4
Autor:
Edward J. Kim, Elizabeth J. Davis, Mark M. Zalupski, Kevin McDonnell, Kent A. Griffith, Joshua M. Ruch
Publikováno v:
American journal of clinical oncology, vol 41, iss 2
Objectives Combinations of gemcitabine, 5-fluorouracil (5-FU), and platinum have demonstrated improved outcomes compared with singlet chemotherapy in pancreatic and biliary cancers. This phase II study examined efficacy and safety of a novel schedule
Autor:
Joshua M. Ruch, Edward J. Kim
Publikováno v:
Drugs. 73(7)
The Hedgehog (Hh) pathway is a developmental signaling pathway involved in numerous developmental processes, including determination of cell fate, patterning, proliferation, survival, and differentiation. While this pathway is silenced in most adult
Autor:
Charles S. Abrams, Thomas C. Abshire, Suzanne A. Arinsburg, Scott T. Avecilla, Aleksandar M. Babic, Michael Bellone, Carolyn M. Bennett, Michael A. Briones, James B. Bussel, Wayne L. Chandler, Marie Csete, Adam C. Cuker, Melissa M. Cushing, Marie-Laure Desormeaux, Roger Y. Dodd, Amy L. Dunn, Richard O. Francis, Jennifer Garbaini, Yelena Z. Ginzberg, Raymond P. Goodrich, Cheryl A. Goss, Benjamin J. Greco, Jeanne E. Hendrickson, Christopher D. Hillyer, Eldad A. Hod, Heather A. Hume, Florencia G. Jalikis, Shawn M. Jobe, Casssandra D. Josephson, Matthew S. Karafin, Sadiqa Karim, Louis M. Katz, Christine L. Kempton, Debra A. Kessler, Devika Lal, Michele P. Lambert, Wendy Lim, Irina Knezevic Maramica, Susanne Marschner, Catherine E. Mcguinn, Shannon L. Meeks, Connie H. Miller, W. Beau Mitchell, Grace F. Monis, Theresa Nester, Huy Phu Pham, Eva D. Quinley, Hanna Rennert, Morayma Reyes, Anna-Sophie Rich, Mikhail Roshal, Joshua M. Ruch, William J. Savage, Andromachi Scaradavou, Joseph Schwartz, Beth H. Shaz, Patricia Shi, Suman Sood, Rona S. Weinberg, Connie M. Westhoff, Anne M. Winkler, Jiong Yan, James C. Zimring
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b73514ff4a0bf6da6b10133c44f901d
https://doi.org/10.1016/b978-0-12-397164-7.01002-8
https://doi.org/10.1016/b978-0-12-397164-7.01002-8
Autor:
Suman L. Sood, Joshua M. Ruch
Bleeding disorders are common in patients with cancer. The vasculature, platelet number and function and coagulation system may all be adversely affected by the malignancy and/or its treatments. While the cause of bleeding may be straightforward in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c621e243eb1ab1b996e3ece1d4b99b54
https://doi.org/10.1016/b978-0-12-397164-7.00119-1
https://doi.org/10.1016/b978-0-12-397164-7.00119-1
Autor:
Vaibhav Sahai, Edward J. Kim, David B. Zhen, Mark M. Zalupski, Joshua M. Ruch, Meredith A. Morgan, Kent A. Griffith, Diane M. Simeone
Publikováno v:
Journal of Clinical Oncology. 34:334-334
334 Background: Hepatocyte growth factor (HGF) and its receptor (c-Met) are activated in pancreatic ductal adenocarcinoma (PDAC). Preclinical data showed a combination of cabozantinib (cabo) and gemcitabine (gem) improved tumor control through inhibi
Autor:
Joshua M, Ruch, Maha H, Hussain
Publikováno v:
Oncology (Williston Park, N.Y.). 25(6)
Improving survival in metastatic castration-resistant prostate cancer (CRPC) is no longer an elusive goal. With the expansion of knowledge regarding the biology of the disease, we are witnessing a plethora of novel therapeutics that are undergoing te
Autor:
Thomas W. Wakefield, Emily Bellile, Suman L. Sood, Joshua M. Ruch, Michelle A. Anderson, Angela E. Hawley
Publikováno v:
Blood. 120:3398-3398
Abstract 3398 INTRODUCTION: VTE is common in patients with cancer and causes significant morbidity and mortality. Clinical risk models and biomarkers including C-reactive protein (CRP), soluble P-selectin (sPsel), and D-dimer have been used to predic
Publikováno v:
Blood. 120:364-364
Abstract 364 Introduction: VTE is a common complication in hospitalized medical patients and the role of pharmacologic anticoagulation prophylaxis is well-established. Patients with active malignancy are at higher risk for VTE during hospitalization.
Publikováno v:
Journal of Clinical Oncology. 30:e14578-e14578
e14578 Background: The incidence of VTE is increased in pancreatic cancer. Predictive models for cancer-associated VTE have been developed, but none specific for the pancreas. Our primary objective was to identify risk factors for VTE in outpatients